This was further validated in a model of human iPSC-derived neurons subjected to the EthD-1 assay, the most stringent and relevant assay to the mechanism of complement and MAC-mediated cytotoxicity, in which co-treatment with CD59 blocked the AD AEV-mediated membrane disruption (AD vs. AD plus CD59 AEVs, p = 0.009; AD plus CD59 vs. Normal AEVs, p = 0.863) (Figure 5b,c). Here, CD59 is linked to Alzheimer disease.